| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
It is desirable to develop a therapeutic means to down-modulate immune responses in an antigen-specific manner without causing systemic immune suppression. In the present study, we found that the severity of experimental autoimmune encephalomyelitis (EAE) induced by myelin autoantigen, myelin basic protein (MBP), was also decreased after treatment with genetically modified embryonic stem cell-derived dendritic cells (ES-DC) presenting another myelin autoantigen, myelin oligodendrocyte glycoprotein (MOG) peptide, and simultaneously expressing TRAIL (ES-DC-TRAIL/MOG). This preventive effect was related to regulatory T cells (Treg). For the treatment of organ-specific autoimmune diseases, induction of Treg reactive to the organ-specific autoantigens by the transfer of DC-presenting antigens and simultaneously overexpressing TRAIL therefore appears to be a promising strategy.
|
